摘要:
Provided are an intermediate compound for preparing rosuvastatin calcium and a preparation method of the rosuvastatin calcium. The method comprises: using the foregoing intermediate compound as a raw material, and subjecting the raw material to a step of Wittig reaction, a step of protecting group removal and hydrolysis and a step of calcium salt formation, so as to obtain the rosuvastatin calcium. The product, which is prepared from the intermediate compound, can be substantially enhanced in stereoselectivity and also notably improved in purity and yield; in addition, the method for preparing rosuvastatin calcium from the intermediate compound is simple, convenient and low in cost.
摘要:
Provided are an intermediate compound for preparing rosuvastatin calcium and a preparation method of the rosuvastatin calcium. The method comprises: using the foregoing intermediate compound as a raw material, and subjecting the raw material to a step of Wittig reaction, a step of protecting group removal and hydrolysis and a step of calcium salt formation, so as to obtain the rosuvastatin calcium. The product, which is prepared from the intermediate compound, can be substantially enhanced in stereoselectivity and also notably improved in purity and yield; in addition, the method for preparing rosuvastatin calcium from the intermediate compound is simple, convenient and low in cost.
摘要:
There are provided compounds of formula I, wherein R1, R1A, R1C to R1E, Ra, Rb, X1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
摘要:
A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein the groups are as defined in the claims. Further aspects of the invention relate to pharmaceutical compositions comprising compounds of formula (I), and the use of compounds of formula (I) in the preparation of a medicament for treating a viral disorder.
摘要:
Compounds represented by general formula (I), tautomers thereof, prodrugs of both, pharmaceutically acceptable salts of them, or solvates thereof exhibit an integrase-inhibiting activity. In said formula, X is hydroxyl or the like; Y is -C(=R?2)-R3-R4¿ (wherein R?2 and R3¿ are each oxygen or the like; and R4 is hydrogen or optionally substituted alkyl), optionally substituted heteroaryl, or the like; Z is hydrogen or the like; Z?1 and Z3¿ are each independently a single bond, alkylene, or the like; Z2 is a single bond, alkylene, -O-, or the like; R1 is optionally substituted aryl, optionally substituted heteroaryl, or the like; p is 0 to 2; and A is an optionally substituted aromatic heterocycle.
摘要:
Pyrimidinone compounds, their preparation and use thereof are disclosed. The said compounds are HMG-CoA reductase inhibitors, and can be used for the treatment and prophylaxis of cardiovascular disease, senile dementia, diabetes, osteoporosis and cancer, and shows anti-viral activity and immunity-enchancing activity, especially suitable for the treatment of hyperlipidemics-related diseases.